INCY News and Press, Incyte Corporation From 08/24/21

Incyte Announces Health Canada Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Canada NewsWire - Minjuvi is an important new therapeutic option for eligible p...

Sino Biological completed a $772 million IPO on Shenzhen's ChiNext Exchange. On the first day of trading, the stock closed 68% higher at a market capitalization of $5.2 billion. Beijing InnoCare in-licensed greater China rights to a CD19 targeting mAb from Delaware-based Incyte in a $...

Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holds 48...

Incyte (NASDAQ:INCY) and InnoCare (HKEX: 09969) today announced that Incyte and a subsidiary of InnoCare have entered into a collaboration and license agreement for the development and commercialization of tafasitamab, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody...

Incyte Corp is a biopharmaceutical company conducting both commercial and clinical development operations. According to the most recent quarterly report, Incyte Corporation appears to see that growth is returning to pre-covid levels. In 2025, if the FDA does not approve many more ...

Incyte's shares have been struggling as diversification away from Jakafi/Jakavi remains a hot issue and challenge. Despite some recent approvals, this process takes time and moves slowly. With still quite a few years left until exclusivity of its blockbuster ends, and other approv...

Growth stocks are grabbing investors’ attention due to continuing economic growth thanks to fiscal and monetary stimulus. And because the market remains highly volatile now on concerns over the resurgence of COVID-19 cases, we think it could be wise to take advantage of the price dips ...

Using the quarterly 13F filings we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. After the Q1-2021 13F filings the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holds 48 s...

The U.S. Food and Drug Administration (FDA) recently issued a complete response letter for Incyte 's (NASDAQ: INCY) PD-1 drug retifanlimab. The PD-1 and PD-L1 immunotherapy market was already getting crowded with eight drugs already approved in the U.S. In this Motley Fool Li...

Image source: The Motley Fool. Incyte Corporation (NASDAQ: INCY) Q2 2021 Earnings Call Aug 3, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Incyte Corporation (INCY) Q2 2021 Earnings Call Transcript